CraniopharyngiomaSymptoms, Doctors, Treatments, Advances & More
Learn About Craniopharyngioma
View Main Condition: Brain Tumor
A craniopharyngioma is a noncancerous (benign) tumor that develops at the base of the brain near the pituitary gland.
The exact cause of the tumor is unknown.
This tumor most commonly affects children from 5 to 10 years of age. Adults can sometimes be affected. Boys and girls are equally likely to develop this tumor.
Craniopharyngioma causes symptoms by:
- Increasing pressure on the brain, usually from hydrocephalus
- Disrupting hormone production by the hypothalamus or pituitary gland
- Pressure or damage to the optic nerve
Increased pressure on the brain can cause:
- Headache
- Nausea
- Vomiting (especially in the morning)
- Change in appetite and weight
- Confusion and drowsiness
Damage to the pituitary gland causes hormone imbalances that can lead to excessive thirst and urination, and slow growth.
When the optic nerve is damaged by the tumor, vision problems develop. These defects are often permanent. They may get worse after surgery to remove the tumor.
Behavioral and learning problems may be present.
The goal of the treatment is to relieve symptoms. Usually, surgery has been the main treatment for craniopharyngioma. However, radiation treatment instead of surgery or along with a smaller surgery may be the best choice for some people.
In tumors that cannot be removed completely with surgery alone, radiation therapy is used. If the tumor has a classic appearance on CT scan, a biopsy may not be needed if treatment with radiation alone is planned. In some people, a shunt may be placed to treat the hydrocephalus.
Stereotactic radiosurgery is performed at some medical centers.
This tumor is best treated at a center with experience in treating craniopharyngiomas.
UPMC Neurological Institute - Presbyterian
Dr. Gardner is the Peter J. Jannetta Endowed Chair of neurological surgery at the University of Pittsburgh School of Medicine and director of the Center for Skull Base Surgery. He specializes in endoscopic endonasal skull base surgery, pituitary tumors, Neuroendoport brain surgery, and vascular neurosurgery. Dr. Gardner is rated as an Elite provider by MediFind in the treatment of Craniopharyngioma. He is also highly rated in 61 other conditions, according to our data. His clinical expertise encompasses Chordoma, Pituitary Tumor, Meningioma, Nerve Decompression, and Endoscopic Transnasal Transsphenoidal Surgery. Dr. Gardner is board certified in American Board Of Neurological Surgery. Dr. Gardner is currently accepting new patients.
Cleveland Clinic Main Campus
Pablo Recinos is a Neurosurgery provider practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 25 years. Dr. Recinos is rated as an Elite provider by MediFind in the treatment of Craniopharyngioma. He is also highly rated in 50 other conditions, according to our data. His clinical expertise encompasses Meningioma, Pituitary Tumor, Cushing's disease, Endoscopic Transnasal Transsphenoidal Surgery, and Balloon Sinuplasty. Dr. Recinos is board certified in American Board Of Neurological Surgery, 2018.
Advocate Medical Group Neurosurgery
Nina Paleologos is a Psychiatrist and a Neurologist practicing medicine in Downers Grove, Illinois. Dr. Paleologos is rated as a Distinguished provider by MediFind in the treatment of Craniopharyngioma. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Oligodendroglioma, Glioma, Glioblastoma, and Astrocytoma. Dr. Paleologos is board certified in American Board Of Psychiatry & Neurology.
In general, the outlook is good. There is an 80% to 90% chance of a cure if the tumor can be completely removed with surgery or treated with high doses of radiation. If the tumor returns, it will most often come back within the first 2 years after surgery.
The outlook depends on several factors, including:
- Whether the tumor can be completely removed
- Which nervous system problems and hormonal imbalances the tumor and treatment cause
Most of the problems with hormones and vision do not improve with treatment. Sometimes, the treatment may even make them worse.
There may be long-term hormone, vision, and nervous system problems after craniopharyngioma is treated.
When the tumor is not completely removed, the condition may return.
Contact your provider for the following symptoms:
- Headache, confusion, drowsiness, nausea, vomiting, or balance problems (signs of increased pressure on the brain)
- Failing to keep up in school
- Loss or gain of weight
- Increased thirst and urination
- Poor growth in a child
- Vision changes
Summary: MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma ...
Summary: ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Published Date: May 10, 2024
Published By: Luc Jasmin, MD, Ph.D., FRCS (C), FACS, Department of Neuroscience, Guam Regional Medical City, Guam; Department of Surgery, Johnson City Medical Center, TN; Department of Maxillofacial Surgery at UCSF, San Francisco, CA. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Lohkamp LN, Kasper EM, Pousa AE, Bartels UK. An update on multimodal management of craniopharyngioma in children. Front Oncol. 2023;13:1149428. PMID: 37213301 pubmed.ncbi.nlm.nih.gov/37213301/.
Styne DM. Physiology and disorders of puberty. In: Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, eds. Williams Textbook of Endocrinology. 14th ed. Philadelphia, PA: Elsevier; 2020:chap 26.
Suh JH, Chao ST, Murphy ES, Recinos PF. Pituitary tumors and craniopharyngiomas. In: Tepper JE, Foote RL, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Philadelphia, PA: Elsevier; 2021:chap 34.
Zaky W. Central nervous system tumors in childhood. In: Kliegman RM, St. Geme JW, Blum NJ, et al, eds. Nelson Textbook of Pediatrics. 22nd ed. Philadelphia, PA: Elsevier; 2025:chap 546.